关于增加 2025 年度日常关联交易预计额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"或"昂利康"）于 2025 年 7 月 4 日召开经营管理层会议，同意公司（包括控股子公司）新增 2025 年度 日常关联交易预计额度 120 万元（不含税），现将具体情况公告如下： 一、日常关联交易基本情况 （一）2025 年度日常关联交易预计情况 公司于 2025 年 4 月 24 日召开了第四届董事会第七次会议和第四届监事会第 五次会议，同意公司及子公司与关联方及其子公司 2024 年度日常关联交易预计 额度为不超过人民币 1,472 万元（不含税），具体内容详见公司在《证券时报》 及巨潮资讯网（www.cninfo.com.cn）上刊载的《关于公司 2025 年度日常关联交 易预计的公告》（公告编号：2025-024）。 证券代码：002940 证券简称：昂利康 公告编号：2025-053 浙江昂利康制药股份有限公司 1、新合新的基本情况 | 公司名称 | ： | 湖南新合新生物医药有限公司 | | | | - ...

Group 1 - The company, Zhejiang Anglikang Pharmaceutical Co., Ltd., announced that its supervisor, Mr. Pan Xiaoyun, plans to reduce his shareholding by up to 159,000 shares, which represents 0.08% of the company's total share capital [1][2] - The reduction period is set from July 28, 2025, to October 27, 2025, following a 15 trading day notice period from the announcement date [1][2] - Mr. Pan holds a total of 638,635 shares, accounting for 0.32% of the company's total share capital, and 0.33% when excluding shares held in the repurchase account [1] Group 2 - The planned reduction will be executed through centralized bidding, and the number of shares to be reduced may be adjusted in case of any changes such as stock dividends or capital increases [2] - The company assures that the reduction plan complies with relevant laws and regulations, and there are no violations of commitments made by shareholders [2][3] - The company emphasizes that this share reduction will not significantly impact its governance structure, ownership structure, or future operations [3]

证券代码：002940 证券简称：昂利康 公告编号：2025-052 浙江昂利康制药股份有限公司 关于监事减持股份的预披露公告 本公司监事潘小云先生保证向公司提供的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）于 2025 年 7 月 3 日收到公司监事潘小云先生的《关于股份减持计划的告知函》，具体内 容如下： 持本公司股份 638,635 股（占本公司总股本比例为 0.32%，占公司剔除回购 专用账户持股数量的总股本比例为 0.33%）的股东潘小云先生计划在本公告披露 之日起 15 个交易日后的 3 个月内（即 2025 年 7 月 28 日至 2025 年 10 月 27 日） 以集中竞价的方式减持本公司股份不超过 159,000 股（占本公司总股本比例为 0.08%，占公司剔除回购专用账户持股数量的总股本比例为 0.08%）。 现将有关情况公告如下： 一、减持主体的基本情况 4、减持期间：自本公告披露之日起 15 个交易日后 3 个月内（即 2025 ...

Core Viewpoint - The company announced that its supervisor, Pan Xiaoyun, plans to reduce his holdings by a maximum of 159,000 shares, which represents 0.08% of the company's total share capital [1] Summary by Relevant Sections - **Shareholding Details** - Pan Xiaoyun currently holds 638,600 shares, accounting for 0.33% of the company's total share capital [1] - The planned reduction will take place between July 28, 2025, and October 27, 2025 [1]

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

证券代码：002940 证券简称：昂利康 公告编号：2025-050 浙江昂利康制药股份有限公司 关于参与投资的股权投资基金变更基金管理人的公告 根据元徕元启管理的实际需要，经元徕元启全体合伙人一致同意元徕元启原 合伙企业管理人上海元徕投资管理有限公司（以下简称"上海元徕"）、原合伙企 业执行事务合伙人上海盈徕企业管理中心（有限合伙）（以下简称"上海盈徕"） 将其所持有的全部普通合伙企业财产份额及相关权益转让给苏州浚迈思元创业 投资管理有限公司（以下简称"苏州浚迈"），此次份额转让后，上海元徕、上海 盈徕不再持有元徕元启的份额，退出元徕元启。苏州浚迈作为元徕元启的普通合 伙人之一，同时担任元徕元启的管理人和执行事务合伙人，元徕元启整体规模不 变。 | 企业名称 | ： | 苏州浚迈思元创业投资管理有限公司 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 统一信用代码 | ： | 91320594MADAW1AK45 | | | | | | 成立时间 | ： | 年 02 | 2024 | 月 | 02 | 日 | | 法定代表人 | ： | | ...

证券代码：002940 证券简称：昂利康 公告编号：2025-051 浙江昂利康制药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的苯磺酸氨氯地平片（5mg、10mg） 《药品注册证书》，现将有关情况公告如下： | 药品通用名称 | 苯磺酸氨氯地平片 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 主要成份 | 苯磺酸氨氯地平 | | | | | | | | | 剂型 | 片剂 | | | | | | | | | 申请事项 | 药品注册（境内生产） | | | | | | | | | 注册分类 | 化学药品 | 类 | 4 | | | | | | | 规格 | 5mg（按 | C₂₀H₂₅ClN₂O₅计） | 10mg（按 | C₂₀H₂₅ClN₂O₅计） | | | | | | 受理号 | CYHS2303561 ...

Core Viewpoint - The company has received the drug registration certificate for Amlodipine Besylate Tablets (5mg, 10mg) from the National Medical Products Administration, which is intended for the treatment of hypertension and symptomatic treatment of coronary heart disease [1] Group 1 - The drug registration certificate is equivalent to passing the consistency evaluation, which will further enrich the company's product pipeline [1] - The company received the notice of acceptance for the drug marketing application in December 2023 and has recently been approved [1]

Core Viewpoint - The stock of Anglikang has experienced significant volatility, with a cumulative increase of over 200% in closing prices over 24 trading days, raising concerns about potential irrational market speculation [1][4][6]. Company Overview - Anglikang, established in 2001 and headquartered in Shengzhou, Zhejiang, is a modern pharmaceutical company focusing on the production of intermediates, active pharmaceutical ingredients, and formulations, particularly in cardiovascular, oral cephalosporins, nephrology, and anesthetics [2][4]. - The company has primarily focused on advancing the consistency evaluation of generic drugs and the development of new generic drug projects [2]. Innovation Drug Development - The only innovative drug project in development is ALK-N001, which received clinical trial approval in April 2025 and is currently in Phase I trials [1][3]. - ALK-N001 is a globally innovative small molecule conjugate drug designed to activate the tumor microenvironment, showing promising efficacy and safety in preclinical studies [3][5]. Financial Performance - Anglikang's stock price surged from approximately 13 yuan at the beginning of the year to 45 yuan by July 2, 2025, with a total market capitalization of 90.58 billion yuan [4]. - The company reported a revenue of 1.537 billion yuan in 2024, with 97.18% of this revenue coming from the sales of formulations, raw materials, and pharmaceutical intermediates [7]. R&D Investment - In 2024, Anglikang increased its R&D investment to 230 million yuan, a 34% increase from the previous year, accounting for 15% of its operating revenue [5][7]. - Despite the increase in R&D spending, the company has only one innovative drug project, which raises concerns about the adequacy of its R&D pipeline [5][6]. Market Risks - The company has indicated that its stock price volatility may be driven by market sentiment rather than fundamental performance, with a significant disparity between stock price growth and actual revenue performance [6][8]. - Revenue for 2024 is projected to decline by 5.41% year-on-year, primarily due to the impact of policy changes on its key product "Zuo Yi" [6][7]. Future Outlook - Anglikang is also venturing into the pet pharmaceutical sector, having established Anglikang Animal Health in 2021, with several products expected to receive approval in the near future [7]. - The company faces the challenge of managing the risks associated with its reliance on a single innovative drug project while planning for a more diversified R&D pipeline to stabilize market confidence [8].

Market Overview - On July 2, the Shanghai Composite Index fell by 0.09%, with institutional investors appearing on the trading lists of 32 stocks, net buying 9 and net selling 23 [1][2] - The total net selling amount by institutional investors reached 641 million yuan [1] Institutional Trading Highlights - The stock with the highest net buying from institutional seats was Anglikang, which closed at the daily limit with a trading volume of 927 million yuan and a turnover rate of 11.45%, net buying amounting to 100.91 million yuan [2][5] - Feiya Technology also closed at the daily limit, with a trading volume of 1.549 billion yuan and a turnover rate of 23.87%, net buying 69.19 million yuan [2][5] - Xinhenghui saw a decline of 5.43% with a turnover rate of 47.06%, net buying 45.42 million yuan [2][5] Performance of Net Bought Stocks - Stocks that were net bought by institutions showed an average increase of 2.57%, outperforming the Shanghai Composite Index [3] - Stocks like Xiangqiang Co. and Kangda New Materials reported strong performances, closing at the daily limit [3] - Historical data indicates a 54.87% probability of net bought stocks rising the next day, with a 51.62% chance of outperforming the index [3] Earnings Forecasts - Among the stocks net bought by institutions, only one stock, Xinhenghui, provided a half-year earnings forecast, expecting a net profit of 106 million yuan, representing a year-on-year increase of 4.59% [3] Net Sold Stocks - The stock with the highest net selling was Changqing Technology, with a net selling amount of 177.81 million yuan, and a turnover rate of 56.72% [3][6] - North Copper, with a net selling of 102.36 million yuan, had a volatility of 16.01% [4][6] - Hongbaoli experienced a net selling of 79.41 million yuan, with a turnover rate of 46.13% [4][6] Southbound Trading Activity - On July 2, 19 stocks on the trading list had southbound trading activity, with net buying in stocks like Rongfa Nuclear Power and Kaimete Gas, amounting to 123 million yuan and 96.13 million yuan respectively [7][9] - Stocks like Hongye Futures and Xiexin Energy saw net selling amounts of 33.58 million yuan and 29.89 million yuan respectively [7][9]